News
BPTSY
1.380
NaN%
--
Weekly Report: what happened at BPTSY last week (1019-1023)?
Weekly Report · 1d ago
Biophytis Calls November 12 General Meeting as BIO101 Programs Advance
TipRanks · 3d ago
Weekly Report: what happened at BPTSY last week (1012-1016)?
Weekly Report · 10/19 09:27
Weekly Report: what happened at BPTSY last week (1005-1009)?
Weekly Report · 10/12 09:28
Weekly Report: what happened at BPTSY last week (0928-1002)?
Weekly Report · 10/05 09:28
Weekly Report: what happened at BPTSY last week (0921-0925)?
Weekly Report · 09/28 09:27
Weekly Report: what happened at BPTSY last week (0914-0918)?
Weekly Report · 09/21 09:27
Biophytis Raises €5.3 Million to Fully Fund Phase 2 Obesity Trial
TipRanks · 09/14 10:28
Weekly Report: what happened at BPTSY last week (0907-0911)?
Weekly Report · 09/14 09:28
Biophytis Expands Obesity Trial to Test BIO101’s Role in Semaglutide Weight-Rebound Control
TipRanks · 09/09 15:17
Weekly Report: what happened at BPTSY last week (0831-0904)?
Weekly Report · 09/07 09:26
Biophytis Bolsters Cash and Cuts Debt Ahead of 2027 Trial Milestones
TipRanks · 08/31 16:57
Weekly Report: what happened at BPTSY last week (0824-0828)?
Weekly Report · 08/31 09:28
Biophytis Files 2025 Annual Financial Report with U.S. SEC
TipRanks · 08/27 15:51
Biophytis Advances Hong Kong Joint Venture to Fund Global Phase 3 Sarcopenia Trial
TipRanks · 08/26 16:27
Weekly Report: what happened at BPTSY last week (0817-0821)?
Weekly Report · 08/24 09:29
Weekly Report: what happened at BPTSY last week (0810-0814)?
Weekly Report · 08/17 09:29
Biophytis Wins Brazilian Approval for Phase 2 Obesity Trial of BIO101
TipRanks · 08/10 23:03
Weekly Report: what happened at BPTSY last week (0803-0807)?
Weekly Report · 08/10 09:27
Weekly Report: what happened at BPTSY last week (0727-0731)?
Weekly Report · 08/03 09:27
More
Webull provides a variety of real-time BPTSY stock news. You can receive the latest news about Biophytis Sa through multiple platforms. This information may help you make smarter investment decisions.
About BPTSY
Biophytis SA, formerly Institut Biophytis Sas is a France-based company engaged in the healthcare industry. The Company is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.